Haemodynamic effects of endothelin receptor antagonist, tezosentan, in tumour necrosis factor-α treated anaesthetized rats

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 367, Issue 2, 2003, Pages 156-167

  Tabrizchi, Reza ^a   Ford, Carol Ann ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Arterial resistance; Blood pressure; Cardiac output; Endothelin receptor antagonist; Mean circulatory filling pressure; Nitric oxide; Tumour necrosis factor

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; NITRATE; NITRIC OXIDE SYNTHASE; NITRITE; TEZOSENTAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; HEART HEMODYNAMICS; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; NONHUMAN; RAT; SYSTEMIC VASCULAR RESISTANCE; VENOUS RETURN;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMODYNAMIC PROCESSES; INFUSIONS, INTRAVENOUS; LUNG; MALE; NITRATES; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; TETRAZOLES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS;

EID: 0037291854     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-002-0663-6     Document Type: Article

References (35)

1. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
2. Clozel M, Ramuz H, Clozel JP, Breu V, Hess P, Loffler BM, Coassolo P, Roux S (1999) Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 290:840-846
3. Clozel M, Qiu C, Qiu CS, Hess P, Clozel JP (2002) Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction. J Am Coll Cardiol 39:142-147
4. DeMeules JE, Pigula FA, Mueller M, Raymond SJ, Gamelli RL (1992) Tumor necrosis factor and cardiac function. J Trauma 32:686-692
5. 2 and sphingosine. Br J Pharmacol 124:493-498
6. Edmunds NJ, Lal H, Woodward B (1999) Effects of tumour necrosis factor-α on left ventricular function in the rat isolated perfused heart: possible mechanisms for a decline in cardiac function. Br J Pharmacol 126:189-196
7. Eibl G, Buhr HJ, Foitzik T (2002) Therapy of microcirculatory disorders in severe acute pancreatitis: what mediators should we block? Intensive Care Med 28:139-146
8. Goodwin AT, Smolenski RT, Gray CC, Jayakumar J, Amrani M, Yacoub MH (2001) Role of endogenous endothelin on coronary reflow after cardioplegic arrest. J Thorac Cardiovasc Surg 122:1167-1173
9. Greenway CV (1981) Mechanism and quantitative assessment of drug effects on cardiac output with a new model of the circulation. Pharmacol Rev 33:213-251
10. Greenway CV, Lautt WW (1986) Blood volume, the venous system, preload and cardiac output. Can J Physiol Pharmacol 64:383-387
11. A receptor antagonist BQ-123, blocks the vasoconstriction induced by sarafotoxin 6b in the heart but not in other vascular beds. Gen Pharmacol 26:183-193
12. Han JJ, Windsor A, Drenning DH, Leeper-Woodford S, Mullen PG, Bechard DE, Sugerman HJ, Fowler AA III (1994) Release of endothelin in relation to tumor necrosis factor-α in porcine Pseudomonas aeruginosa-induced septic shock. Shock 1:343-346
13. Heyman SN, Darmon D, Goldfarb M, Bitz H, Shina A, Rosen S, Breis M (2000) Endotoxin-induced renal failure. I. A role for altered renal microcirculation. Exp Nephrol 8:266-274
14. Hohlfeld T, Klemm P, Thiemermann C, Warner TD, Schror K, Vane JR (1995) The contribution of tumour necrosis factor-α and endothelin-1 to the increase of coronary resistance in hearts from rats treated with endotoxin. Br J Pharmacol 116:3309-3315
15. Joshua IG (1990) Endothelin-induced vasoconstriction of small resistance vessels in the microcirculation of the rat cremaster muscle. Microvasc Res 40:191-198
16. Klemm P, Warner TD, Hohlfeld T, Corder R, Vane JR (1995) Endothelin 1 mediates ex vivo coronary vasoconstriction caused by exogenous and endogenous cytokines. Proc Natl Acad Sci USA 92:2691-2695
17. Kraut EJ, Chen S, Hubbard NE, Erickson KL, Wisner DH (1999) Tumor necrosis factor depresses myocardial contractility in endotoxemic swine. J Trauma 46:900-906
18. Mitaka C, Hirata Y, Ichikawa K, Yokoyama K, Emori T, Kanno K, Amaha K (1994) Effects of TNF-α on hemodynamic changes and circulating endothelium-derived vasoactive factors in dogs. Am J Physiol 267:H1530-H1536
19. Pang CCY (1983) Effect of vasopressin antagonists and saralasin on regional blood flow following hemorrhage. Am J Physiol 245:H749-H755
20. Pang CCY (2001a) Measurement of body venous tone. J Pharmacol Method 44:341-360
21. Pang CCY (2001b) Autonomic control of the venous system in health and disease. Effect of drugs. Pharmacol Ther 90:179-230
22. Pang CCY, Tabrizchi R (1986) The effects of noradrenaline, B-HT 920, methoxamine, angiotensin II and vasopressin on mean circulatory filling pressure in conscious rats. Br J Pharmacol 89:389-394
23. Petrov T, Rafols JA (2001) Acute alteration of endothelin-1 and iNOS expression and control of the brain microcirculation after head trauma. Neurol Res 23:139-143
24. Schalcher C, Cotter G, Reisin L, Bertel O, Kobrin I, Guyene TT, Kiowski W (2001) The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. Am Heart J 142:340-349
25. Schenk J, Hebden A, McNeill, JH (1992) Measurement of cardiac left ventricular pressure in conscious rats using a fluid-filled catheter. J Pharmacol Toxicol Methods 27:171-175
26. Schmidt HHHW, Warner TD, Nakane M, Forstermann U, Murad F (1992) Regulation and subcellular location of nitric oxide synthases in RAW264.7 macrophages. Mol Pharmacol 41:615-624
27. Sonin NV, Garcia-Pagan JC, Nakanishi K, Zhang JX, Clemens MG (1999) Patterns of vasoregulatory gene expression in the liver response to ischemia/reperfusion and endotoxemia. Shock 11:175-179
28. Tabrizchi R (1997) Effects of adenosine and adenosine analogues on mean circulatory filling pressure and cardiac output in anaesthetized rats. Naunyn-Schmiedebergs Arch Pharmacol 356:69-75
29. Tabrizchi R (2001) The influence of tumour necrosis factor-α on the cardiovascular system of anaesthetized rats. Naunyn-Schmiedebergs Arch Pharmacol 363:307-321
30. Thielmann M, Dorge H, Martin C, Belosjorow S, Schwanke U, van De Sand A, Konietzka I, Buchert A, Kruger A, Schulz R, Heusch G (2002) Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumour necrosis factor-α, and sphingosine. Circ Res 90:807-813
31. Thiemermann C, Wu C-C, Szabó C, Perretti M, Vane, JR (1993) Role of tumour necrosis factor in the induction of nitric oxide synthase in a rat model of endotoxin shock. Br J Pharmacol 110:177-182
32. Torre-Amione G, Durand JB, Nagueh S, Vooletich MT, Kobrin I, Pratt C (2001) A pilot safety trial of prolong (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure. Chest 120:460-466
33. Walley KR, Hebert PC, Wakai Y, Wilcox PG, Road JD, Cooper DJ (1994) Decrease in left ventricular contractility after tumor necrosis factor-α infusion in dogs. J Appl Physiol 76:1060-1067
34. Warner TD, Klemm P (1996) What turns on the endothelins? Inflamm Res 45:51-53
35. Wilson MA, Steeb GD, Garrison RN (1993) Endothelin mediates intestinal hypoperfusion during bacteremia. J Surg Res 55:168-175